Company: ADPT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001193125-25-267061
Chunk: 3

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1A
Chunk 3
---
 providing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions. This may cause our Immune Medicine revenue not to be comparable to prior periods. Although we will cease incurring Immune Medicine research and development expenses associated with the Genentech Agreement, this may result in less innovation and business growth, and any other research and development efforts we pursue may not be successful, which would negatively impact our business and financial condition.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.